Kimberly White - Vertex Pharmaceuticals President

VRTX -- USA Stock  

Earning Report: October 23, 2019  

  President
Ms. Kimberly A. White is Senior Vice President and Chief Communications Officer of the Company. She spent the last seven years at Edelman, where she headed the agency global healthcare sector and led a team of 600 people worldwide. During her time at Edelman, Ms. White developed and implemented U.S. and global communications programs for a wide variety of companies and organizations in the healthcare industry. Before Edelman, she was the Chief Communications Officer at Baxter International Inc., where she led Baxter global communications function. Ms. White also spent more than 15 years with Ogilvy PR Worldwide, including as the CoManaging Director of the agency global healthcare practice. Ms. White will be responsible for leading the global corporate communications function, spanning product communications, media relations, digital and social communications, internal communications, corporate social responsibility and community affairs
  President Since 2018      
617 341-6100  www.vrtx.com
White most recently served as Global Chair of the Health Sector at Edelman.

Management Efficiency

The company has return on total asset (ROA) of 9.99 % which means that it generated profit of $9.99 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 56.25 % meaning that it created $56.25 on every $100 dollars invested by stockholders.
The company currently holds 656.95 M in liabilities with Debt to Equity (D/E) ratio of 12.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.67 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Glenn DavidZoetis
2016
Michael AbermanRegeneron Pharmaceuticals
2015
Sripada ChandrasekharDr Reddys Laboratories Ltd
2013
Andrew FentonZoetis
2018
K RaoDr Reddys Laboratories Ltd
2016
Heidi ChenZoetis
2012
Michael StewartPerrigo Company Plc
2004
Thomas FarringtonPerrigo Company Plc
2015
Paul WeningerPerrigo Company Plc
2015
Alejandro BernalZoetis
2015
Scott JamisonPerrigo Company Plc
2011
James DillardPerrigo Company Plc
2019
Stefan WeiskopfZoetis
2013
John WesolowskiPerrigo Company Plc
2016
James MichaudPerrigo Company Plc
2016
Ronald JanishPerrigo Company Plc
2015
Jay MarkowitzRegeneron Pharmaceuticals
2017
Joseph LaRosaRegeneron Pharmaceuticals
2019
Svend AndersenPerrigo Company Plc
2017
Sandra BeatyZoetis
2012
Daniel PlewRegeneron Pharmaceuticals
2016

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Did you try this?

Run Balance Of Power Now

   

Balance Of Power

Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
All  Next Launch Module

Also Currentnly Active

Purchased over 100 shares of
a day ago
Traded for 24.76
Purchased over 200 shares of
a day ago
Traded for 53.38
Purchased over 60 shares of
a day ago
Traded for 78.1
Also please take a look at World Market Map. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.
Search macroaxis.com